CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Newest patents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team


Dinuclear metallic complexes for the capture of cellular microparticles



Patents status

Priority patent application n°FR1100873 filed on March 23, 2011 entitled “Complexes métalliques dinucléaires greffés, et leur utilisation en tant que capteurs de microparticules cellulaires”


Catherine BELLE

commercial status

Exclusive or non-exclusive licenses, Collaborative agreement


Centre d’imagerie – neurosciences et d’applications aux pathologies (CI-NAPS)



It is now well demonstrated that circulating platelets and blood cells (leucocytes, red cells) as well as endothelial cells are capable of releasing membrane microparticles under the influence of a variety of stimuli. Although more than 80 % of blood microparticles are of platelet origin, variations in the relative amount of one or the other microparticles may be characteristically found in specific pathologies. This is why there is an urgent need for non-invasive detection of cell-derived microparticles in a variety of pathologies including atherosclerotic vascular disease, diabetes, cancer, and autoimmune systemic and inflammatory diseases. Although an increasing literature exists on the alterations of microparticle subpopulations in various disease states, current analytical methods are inaccurate for their detection, identification and quantification in plasma.



There is currently no available test in the routine laboratory to accurately evaluate in biological fluids the properties and role of microparticles as potential biomarkers of specific cell or tissue activation processes in a number of pathologies. Inventors have developped a novel synthetic ligand for phosphatidylserine that allows capture, origin identification and functional analysis of microparticles including fibrinolytic activity, using specific antibodies and reagents. This is the first test assay available for routine clinical practice that allows multipurpose characterization of microparticles.


  • The advantage of the proposed method is that the ligand is a synthetic compound that does not present potential complications encountered with the use of a biological molecule (inhibitors, interference with other ligands including antibodies, proteolysis, sensitivity to calcium). As proposed, this test could be easily performed in a routine laboratory setting using a capture procedure and single step detection without requirement of expensive or multiple purified reagents. It will therefore be both clinically useful and economically advantageous.


Detection, identification and quantificationof microparticles in plasma.


The technic was developed using microparticles derived from cultured monocytic and endothelial cell lines.
The procedure is now being extended to microparticles in a plasma milieu and other biological fluids (e.g. urine, saliva).
Alternatively to microplates, beads will be used as support.

For further information, please contact us (Ref 03818-02)


Need further information ?

Contact us

Contact us

  • This field is for validation purposes and should be left unchanged.

Newest patents